| Autor: |
Laurent, Guy, de Micheaux, Sylvie Lafaye, Solal-Celigny, Philippe, Soubeyran, Pierre, Delwail, Vincent, Ghesquières, Hervé, Thieblemont, Catherine, Jourdan, Eric, Beautier, Lucile, Audibert, Fabien, Squiban, Patrick, Sicard, Helene, Rossi, Jean-Francois |
| Zdroj: |
Blood; November 2009, Vol. 114 Issue: 22 p1649-1649, 1p |
| Abstrakt: |
We report here the end of recruitment and updated data on 45 patients and more than 100 cycles of IPH1101. Overall safety was good, and most of the drug-related adverse events were, as expected, flu like symptoms of grade 1 or 2. The SAEs reported were 2 hypotensions, 1 bronchospasm, 1 allergic reaction (back pain), 1 glomerular filtration decrease, 1 ALAT elevation, 1 hypertension and 1 asthenia.The immuno-biological follow up demonstrated the very good pharmacodynamic profile of IPH1101 in these patients and these data are presented in details in another abstract from Lucas et al.To date, in the first set of evaluable patients (12 pts) and after at least 3 months post treatment, investigators reported about 75% of response and 50% of CR. Most of the responses are already confirmed by an independent panel.These observations confirm the good safety and the biological rationale of this approach. Furthermore, the response rate in this first set of pts is encouraging in the context of previously treated patients. Updated results will be presented at the meeting.Laurent: Innate pharma: Honoraria. Lafaye de Micheaux:Innate Pharma: Employment. Solal-Celigny:Innate Pharma: Research Funding. Soubeyran:Innate Pharma: Research Funding. Delwail:Innate Pharma: Honoraria. Ghesquières:innate pharma: Honoraria. Thieblemont:Innate Pharma: Honoraria. Jourdan:Innate Pharma: Honoraria. Beautier:Innate Pharma: Employment. Squiban:Innate pharma: Employment. Rossi:Innate Pharma: Honoraria. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
